Condition: Non Small Cell Lung Cancer · Sponsor: University of Leeds
CONCORDE is a multi-institution, multi-arm, Phase IB study that will determine the recommended phase II dose (RP2D) and safety profiles of different DNA damage repair inhibitors (DDRis) when given in an open label fashion in combination with fixed dose curative intent radiotherapy (RT) in patients with stage IIB/IIIA/IIIB NSCLC, followed by up to 12 months of consolidation durvalumab immunotherapy in selected study arms. The RP2D will be evaluated by incorporating the number of observed dose limiting toxicities (DLTs) into a time to event continuous reassessment method (TiTE- CRM) model within each of the experimental arms. TiTE-CRM is used here to take into account longer-term toxicities up to 13.5 months post start of radiotherapy and use these to inform dose escalation decision making.
This description comes directly from the study's public registry record.
Jamie B Oughton, MPhil · 0113 343 1494 · CTRU_CONCORDE@Leeds.ac.uk
Always discuss trial participation with your own doctor first.
| Belfast City Hospital | Belfast, United Kingdom | Recruiting |
| Birmingham Heartlands Hospital | Birmingham, United Kingdom | Recruiting |
| Addenbrooke's Hospital | Cambridge, United Kingdom | Recruiting |
| Velindre Cancer Centre | Cardiff, United Kingdom | Recruiting |
| The Royal Marsden Hospital Chelsea | Chelsea, United Kingdom | Recruiting |
| Western General Hospital | Edinburgh, United Kingdom | Recruiting |
| St James's University Hospital | Leeds, United Kingdom | Recruiting |
| The Clatterbridge Cancer Centre | Liverpool, United Kingdom | Recruiting |
| St Bartholomew's Hospitals | London, United Kingdom | Recruiting |
| University College Hospital London | London, United Kingdom | Recruiting |
| The Christie NHS Foundation Trust | Manchester, United Kingdom | Recruiting |
| Freeman Hospital, Newcastle upon Tyne Hospitals NHS Trust | Newcastle upon Tyne, United Kingdom | Recruiting |
+ 2 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04550104